Cartesian Therapeutics Inc
RNAC
Market Cap$405.75M
Close$
$-8.19
134% downside
Current Fair Value
134% downsideOvervalued by 134% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $405.75 Million |
|---|---|
| Enterprise Value | $312.79 Million |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-64.73 |
| Beta | 0.0 |
| Outstanding Shares | 17,796,053 |
| Avg 30 Day Volume | 99,688 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -1.59 |
|---|---|
| PEG | -0.98 |
| Price to Sales | 24.06 |
| Price to Book Ratio | -3.44 |
| Enterprise Value to Revenue | 12.07 |
| Enterprise Value to EBIT | -3.84 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | -0.09 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Cartesian Therapeutics Inc
81 employees
CEO: Carsten Brunn selecta biosciences, inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. selecta plans to combine its tolerogenic synthetic vac...